PDR MEMBER LOGIN:
  • PDR Search

    Required field
  • Advertisement
  • FDA Date: 07/08/2010

    Qualaquin (quinine sulfate) FDA Drug Safety Communication

    New Risk Management Plan and Patient Medication Guide for Qualaquin (quinine sulfate)

    This information reflects FDA's current analysis of data available to FDA concerning this drug. FDA intends to update this sheet when additional information or analyses become available.

    Due to continued reports of serious side effects in patients using Qualaquin "off-label" (non-FDA-approved use) for nighttime leg cramps, the FDA has approved a risk management plan to warn against the use of this drug for such unapproved uses. Qualaquin should not be used for nighttime leg cramps. Qualaquin is ONLY FDA-approved for the treatment of uncomplicated malaria caused by the parasite Plasmodium falciparum, a rare infection in the United States, primarily in travelers returning from malaria-endemic areas.

    The risk management plan, called a Risk Evaluation and Mitigation Strategy (REMS), requires that patients be given a Medication Guide explaining what this medication is and is not approved for, as well as the potential side effects of this drug. In addition, the REMS requires that the manufacturer issue a Dear Health Care Provider (DHCP) Letter warning of the risk of serious and life-threatening hematologic (blood-related) reactions.

    View the full FDA Drug Safety Communication on FDA.gov